WASHINGTON (dpa-AFX) - The U.S. Food and Drug Administration has approved the Zycubo (copper histidinate) injection as the first treatment for Menkes disease in pediatric patients.
'With today's action, children with this devastating, degenerative disease will have an FDA-approved treatment option and the potential to live longer,' said Christine Nguyen, Deputy Director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDA's Center for Drug Evaluation and Research. 'The FDA will continue to work with the rare disease community to advance drug development for patients with Menkes disease and other rare conditions.'
Menkes disease is a neurodegenerative disorder caused by a genetic defect that impairs a child's ability to absorb copper. The disease is characterized by seizures, failure to gain weight and grow, developmental delays, and intellectual disability. It leads to abnormalities of the vascular system, bladder, bowel, bones, muscles, and nervous system. Children with classical Menkes begin to develop symptoms in infancy and typically do not live past three years. It affects approximately one in every 100,000-250,000 live births worldwide and is more common in boys.
Zycubo is a copper replacement therapy given by subcutaneous injection. It delivers copper in a form that bypasses the genetic defect in intestinal absorption, allowing the body to better use the mineral.
The FDA evaluated Zycubo in two open-label, single-arm clinical trials in pediatric patients treated for up to three years. Overall survival was assessed by comparing treated patients to untreated patients from contemporaneous external control groups. The analysis included 66 treated patients and 17 untreated patients, most of whom were from the United States.
Children who began treatment within four weeks of birth had a 78 percent reduction in the risk of death compared with untreated patients, FDA says. Nearly half of early-treated patients survived beyond six years, and some survived more than 12 years. No patients in the untreated control group survived beyond six years. Children who started treatment later than four weeks after birth also experienced a substantial survival benefit.
The most common side effects reported with Zycubo included infections, respiratory problems, seizures, vomiting, fever, anemia and injection site reactions. FDA warned that because copper can accumulate in the body, patients receiving Zycubo should be closely monitored for potential toxicity.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
